BioSpace News Archive

Drug Development

HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients

Human Immunology Biosciences, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases, announced positive results from a Phase 2 investigator-sponsored clinical trial of felzartamab for late antibody-mediated rejection in kidney transplant recipients.

May 25, 2024
·
7 min read
Drug Development

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Novartis presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® at the late-breaking clinical trials session of the European Renal Association Congress.

May 25, 2024
·
16 min read
Drug Development

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio

Novartis presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A receptor antagonist, in patients with IgA nephropathy 1.

May 25, 2024
·
15 min read
Drug Development

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Vera Therapeutics, Inc. announced data presentations from its Phase 2b ORIGIN trial of atacicept in immunoglobulin A nephropathy, showing that atacicept stabilized kidney function through 72 weeks and led to rapid improvements in hematuria.

May 25, 2024
·
10 min read